Scholarlink

Purpose of review <p>Despite advances in type 1 diabetes (T1D) management, mortality is still increased, with cardiovascular disease (CVD) as the leading cause. Dyslipidemia is a highly prevalent modifiable CVD risk factor. We reviewed the existing literature on CVD mortality in T1D to highlight CVD risk in pediatric patients with T1D.</p> Recent findings <p>Pathophysiology of T1D and premature CVD risk is still not fully understood. Dyslipidemia remains a highly prevalent and undertreated CV risk factor in T1D. Statins have been shown to be safe and effective to improve CVD risk in adults with T1D, and in children with familial hypercholesterolemia, in addition to improving lipids levels in children with T1D.</p> Summary <p>T1D is associated with premature CVD mortality, and dyslipidemia is still a highly prevalent and undertreated CVD risk factor. We aim to educate and empower pediatric providers to optimize management of dyslipidemia in pediatric patients with T1D to potentially decrease the CVD risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiovascular Disease and Dyslipidemia in Pediatric Type 1 Diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Grace K. Kim,
  • Preneet Cheema Brar,
  • Nidhi Bansal

摘要

Purpose of review

Despite advances in type 1 diabetes (T1D) management, mortality is still increased, with cardiovascular disease (CVD) as the leading cause. Dyslipidemia is a highly prevalent modifiable CVD risk factor. We reviewed the existing literature on CVD mortality in T1D to highlight CVD risk in pediatric patients with T1D.

Recent findings

Pathophysiology of T1D and premature CVD risk is still not fully understood. Dyslipidemia remains a highly prevalent and undertreated CV risk factor in T1D. Statins have been shown to be safe and effective to improve CVD risk in adults with T1D, and in children with familial hypercholesterolemia, in addition to improving lipids levels in children with T1D.

Summary

T1D is associated with premature CVD mortality, and dyslipidemia is still a highly prevalent and undertreated CVD risk factor. We aim to educate and empower pediatric providers to optimize management of dyslipidemia in pediatric patients with T1D to potentially decrease the CVD risk.